– Applied DNA’s safeCircle™ Program Integrates
with CLEARED4 Digital Platform for Online Health Safety Management
and Reporting, Option Geared for Scaling of High-Volume Testing
Clients –
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing, announced today that its wholly-owned subsidiary,
Applied DNA Clinical Laboratories, LLC (ADCL) has entered into a
reseller and sales referral partnership with CLEARED4, a
field-proven, New York-based provider of return-to-work health
safety solutions. Under the terms of the partnership, ADCL can
resell subscriptions to CLEARED4’s platform as part of ADCL’s
safeCircle™ pooled COVID-19 surveillance testing program, and
CLEARED4 can refer its clients seeking pooled COVID-19 surveillance
testing to ADCL.
The companies have integrated ADCL’s safeCircle laboratory
testing operations with CLEARED4’s return-to-work health safety
platform as a value-added option for current and prospective ADCL
clients. CLEARED4 has also integrated ADCL’s cost-effective pooled
surveillance testing solution into its HIPAA-compliant platform and
can offer safeCircle to its existing and prospective clients to
enhance their COVID-19 safety protocols. The CLEARED4 platform
recently issued its one-millionth return-to-work Access Pass to its
national client base that is attracted by the platform’s highly
customizable user experience: mobile text and email messaging; a
suite of health-centric modules for surveys and contact tracing and
reporting; on-site kiosks; and now integrated with safeCircle’s
PCR-based pooled surveillance testing and reporting to manage
valuable COVID-19 clearance and to help empower safe re-openings.
ADCL can now offer clients new platform management features
following safeCircle’s integration with CLEARED4, including the
ability to automate the management and monitoring of clients’
surveillance testing programs and ensure timely communication of
valuable testing program results and quarantine compliance.
ADCL’s newest safeCircle client, the Suffolk County (N.Y.)
Government, is utilizing CLEARED4 to manage the reporting of
COVID-19 pooled surveillance testing for portions of its workforce.
Applied DNA also recently purchased an end-user license to deploy
the CLEARED4 platform for its own internal pooled surveillance
testing program for its employees.
Dr. James A. Hayward, president and CEO, Applied DNA, said,
“Partnering with CLEARED4 aligns with our growth expectations for
the safeCircle platform and is especially functional for scaling
high-volume clients. Identifying potential infections early and in
a cost-efficient and rapid manner is how pooled surveillance
testing gets workers back to work, students back to school, and
communities to reopen. With business momentum increasing, we look
to grow and service our safeCircle client base with partners who
offer value-added features.”
Dr. Soumi Eachempati, CEO of Chelsea Health Solutions and
Cleared4, and former Professor of Surgery and Public Health at
Weill Cornell Medical School, stated, “The partnership between
Applied DNA and CLEARED4 offers an unmatched level of COVID-19 risk
mitigation and management to schools and businesses. CLEARED4’s
medically-based software platform has already yielded over one
million access passes. We are poised to create millions more
through this partnership and expansion into entertainment and
sporting venues, as well as dining and travel uses, with our novel
vaccine verification technique.”
About safeCircle™
ADCL’s pooled surveillance testing program, known as
safeCircle™, utilizes frequent, high-sensitivity pooled testing to
help prevent virus spread by quickly identifying infections within
a community, school, or workplace. safeCircle provides 24-hour
results using real-time PCR (RT-PCR) testing.
Click through to learn more about how safeCircle can help your
community, school, and workplace: safeCircle
About the Linea™ COVID-19 Assay Kit and
Pooled Surveillance Testing
The Linea™ COVID-19 Assay Kit is authorized by FDA EUA for the
qualitative detection of nucleic acid from SARS-CoV-2 in
respiratory specimens, including anterior nasal swabs,
self-collected at a healthcare location or collected by a
healthcare worker, and nasopharyngeal and oropharyngeal swabs,
mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal
aspirates, and bronchoalveolar lavage (BAL) specimens collected by
a healthcare worker from individuals who are suspected of COVID-19
by their healthcare provider. The scope of the Linea™ COVID-19
Assay Kit EUA, as amended, is expressly limited to use consistent
with the Instructions for Use by authorized laboratories, certified
under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
to perform high complexity tests. The EUA will be effective until
the declaration that circumstances exist justifying the
authorization of the emergency use of in vitro diagnostics for
detection and/or diagnosis of COVID-19 is terminated or until the
EUA’s prior termination or revocation. The diagnostic kit has not
been FDA cleared or approved, and the EUA’s limited authorization
is only for the detection of nucleic acid from SARS-CoV-2, not for
any other viruses or pathogens.
The Company is offering surveillance testing in compliance with
current CDC, FDA, and CMS guidances. The use of saliva and pooled
sampling for surveillance testing, which has been internally
validated by the Company in compliance with current surveillance
testing guidances, is not included in the Company’s EUA
authorization for the Linea™ COVID-19 Assay Kit.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping, and pre-clinical nucleic acid-based
therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
About CLEARED4
CLEARED4 is one of a suite of health-safety solutions from
Chelsea Health Solutions, a NY company, enabling businesses,
schools, stadiums and municipalities across America to return
safely during this pandemic. CLEARED4 is a patent-pending, HIPAA
compliant platform that provides a higher level of safety,
compliance and automation where communicable health issues could
occur and afflict other individuals. Pioneered from advanced
technology, CLEARED4 includes advanced symptom monitoring,
integrated access control, automated contract tracing, Covid-19
testing and vaccination verification.
Chelsea Health Solutions launched the CLEARED4 platform in April
2020 with CLEARED4WORK, and more recently launched additional
vertical specific health-safety solutions including CLEARED4CLASS,
CLEARED4FANS, CLEARED4DINING and CLEARED4TRAVEL.
CLEARED4 is easy to implement and can be integrated into the
reopening plan of a new client within 24 hours. For more
information, visit www.Cleared4.org.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies, and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to, its history of
net losses, limited financial resources, limited market acceptance,
the uncertainties inherent in research and development, future
clinical data and analysis, including whether any of Applied DNA’s
or its partner’s diagnostic candidates will advance further in the
preclinical research or clinical trial process, including receiving
clearance from the U.S. Food and Drug Administration or equivalent
foreign regulatory agencies to conduct clinical trials and whether
and when, if at all, they will receive final approval from the U.S.
FDA or equivalent foreign regulatory agencies, the unknown outcome
of any applications or requests to U.S. FDA, equivalent foreign
regulatory agencies and/or the New York State Department of Health,
the unknown limited duration of any Emergency Use Authorization
(EUA) approval from U.S. FDA, changes in guidances promulgated by
the CDC, FDA and/or CMS relating to COVID-19 surveillance testing,
disruptions in the supply of raw materials and supplies, and
various other factors detailed from time to time in Applied DNA’s
SEC reports and filings, including our Annual Report on Form 10-K
filed on December 17, 2020, and other reports we file with the SEC,
which are available at www.sec.gov. Applied DNA undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events, or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201229005075/en/
Investor contact: Sanjay M. Hurry, Applied DNA Sciences,
917-733-5573, sanjay.hurry@adnas.com Program contact: Mike
Munzer, Applied DNA Sciences, 631-240-8814, mike.munzer@adnas.com
Web: www.adnas.com,
https://adnas.com/covid-19-surveillance-testing/ Twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024